# An Extention Study of Safety of Canakinumab in Japanese Patients With Periodic Fever Syndromes

> **NCT02911857** · PHASE3 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 4 (actual)

## Conditions studied

- Periodic Fevers Syndrome

## Interventions

- **BIOLOGICAL:** Canakinumab (AIN457)

## Key facts

- **NCT ID:** NCT02911857
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-10-03
- **Primary completion:** 2017-01-27
- **Final completion:** 2017-01-27
- **Target enrollment:** 4 (ACTUAL)
- **Last updated:** 2018-08-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02911857

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02911857, "An Extention Study of Safety of Canakinumab in Japanese Patients With Periodic Fever Syndromes". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT02911857. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*